| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Aging with CF: Characteristics of people with CF aged 40 and older in the United States
|
Ostrenga, Joshua S.
|
|
|
24 |
1 |
p. 183-186
|
artikel
|
| 2 |
A phase I study assessing the safety and tolerability of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T
|
Caraco, Yoseph
|
|
|
24 |
1 |
p. 66-71
|
artikel
|
| 3 |
Assessing the impact of elexacaftor/tezacaftor/ivacaftor on anxiety & depression symptom scores in adults with Cystic Fibrosis
|
Nguyen, Minh
|
|
|
24 |
1 |
p. 26-29
|
artikel
|
| 4 |
A W1282X cystic fibrosis mouse allows the study of pharmacological and gene-editing therapeutics to restore CFTR function
|
Michicich, Margaret
|
|
|
24 |
1 |
p. 164-174
|
artikel
|
| 5 |
Bridging the gap: Challenging lung infections and clinical trial development in cystic fibrosis
|
Downey, Damian G.
|
|
|
24 |
1 |
p. 79-82
|
artikel
|
| 6 |
Cardiometabolic risk factors in adults with cystic fibrosis undergoing elexacaftor/tezacaftor/ivacaftor therapy
|
Gramegna, Andrea
|
|
|
24 |
1 |
p. 53-56
|
artikel
|
| 7 |
CF Ferrets exposed to in utero ivacaftor do not develop lens abnormalities
|
Taylor-Cousar, Jennifer L.
|
|
|
24 |
1 |
p. 19-20
|
artikel
|
| 8 |
Changes in factors associated with inhaled antibiotic prescriptions for people with cystic fibrosis over time in the U.S.
|
Muhlebach, Marianne S.
|
|
|
24 |
1 |
p. 98-104
|
artikel
|
| 9 |
Contents
|
|
|
|
24 |
1 |
p. i-iii
|
artikel
|
| 10 |
Development of metabolic syndrome in people with Cystic Fibrosis one year after exposure to elexacaftor-tezacaftor-ivacaftor
|
Ratti, Gregory A.
|
|
|
24 |
1 |
p. 47-52
|
artikel
|
| 11 |
Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union
|
Costa, Enrico
|
|
|
24 |
1 |
p. 125-132
|
artikel
|
| 12 |
Efficacy and safety of LAU-7b in a Phase 2 trial in adults with cystic fibrosis
|
Konstan, Michael W.
|
|
|
24 |
1 |
p. 83-90
|
artikel
|
| 13 |
Elevated liver function tests in infants exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breastfeeding – Case reports
|
Kolaczkowski, Theresa Jane
|
|
|
24 |
1 |
p. 16-18
|
artikel
|
| 14 |
Elexacaftor/tezacaftor/ivacaftor efficacy in intestinal organoids with rare CFTR variants in comparison to CFTR-F508del and CFTR-wild type controls
|
Kroes, Suzanne
|
|
|
24 |
1 |
p. 175-182
|
artikel
|
| 15 |
ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo
|
Danahay, Henry
|
|
|
24 |
1 |
p. 72-78
|
artikel
|
| 16 |
Evidence for secondary ciliary dyskinesia in patients with cystic fibrosis
|
Bonhiver, Romane
|
|
|
24 |
1 |
p. 193-200
|
artikel
|
| 17 |
Exogenous insulin does not reduce protein catabolism in pre-diabetic cystic fibrosis patients: A randomized clinical trial
|
Schiavon, Michele
|
|
|
24 |
1 |
p. 57-65
|
artikel
|
| 18 |
Factors associated with prescription of elexacaftor/tezacaftor/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele
|
Hergenroeder, Georgene E
|
|
|
24 |
1 |
p. 135-141
|
artikel
|
| 19 |
Gene expression profile of intestinal organoids from people with cystic fibrosis upon exposure to elexacaftor/tezacaftor/ivacaftor
|
Cinek, Ondrej
|
|
|
24 |
1 |
p. 157-163
|
artikel
|
| 20 |
Glucagon-like-peptide-1 agonist therapy in adults with cystic fibrosis
|
Park, Sanghoon
|
|
|
24 |
1 |
p. 40-46
|
artikel
|
| 21 |
Impact of elexacaftor/tezacaftor/ivacaftor on utilization of routine therapies in cystic fibrosis: Danish nationwide register study
|
Råket, Hans Kristian
|
|
|
24 |
1 |
p. 105-111
|
artikel
|
| 22 |
Insights into epithelial-mesenchymal transition from cystic fibrosis rat models
|
Rout-Pitt, Nathan
|
|
|
24 |
1 |
p. 149-156
|
artikel
|
| 23 |
Learning from the CFTR modulator baby boom
|
Jain, Raksha
|
|
|
24 |
1 |
p. 3-4
|
artikel
|
| 24 |
Lens-related ocular changes in fetal rats following in-utero exposure to elexacaftor-tezacaftor-ivacaftor
|
Zhu, Yimin
|
|
|
24 |
1 |
p. 21-25
|
artikel
|
| 25 |
Linkage of the CF Foundation Patient Registry with the Scientific Registry of Transplant Recipients database
|
Cromwell, Elizabeth A.
|
|
|
24 |
1 |
p. 112-117
|
artikel
|
| 26 |
Metabolic syndrome in the post-ETI era
|
Litvin, Marina
|
|
|
24 |
1 |
p. 8-9
|
artikel
|
| 27 |
News article
|
|
|
|
24 |
1 |
p. 1-2
|
artikel
|
| 28 |
Next generation triplex-forming PNAs for site-specific genome editing of the F508del CFTR mutation
|
Gupta, Anisha
|
|
|
24 |
1 |
p. 142-148
|
artikel
|
| 29 |
Process and validity of linking cystic fibrosis patient registry with national Medicaid databases
|
Esther Jr, Charles R.
|
|
|
24 |
1 |
p. 118-124
|
artikel
|
| 30 |
Regulatory adverse drug reaction analyses support a temporal increase in psychiatric reactions after initiation of cystic fibrosis combination modulator therapies
|
O'Connor, Jacob
|
|
|
24 |
1 |
p. 30-32
|
artikel
|
| 31 |
Regulatory delays in approval of CFTR modulating agents in Canada
|
Thornton, Christina S.
|
|
|
24 |
1 |
p. 133-134
|
artikel
|
| 32 |
Self-reported chronic therapy use after 24-weeks of follow-up by participants who completed the simplify randomized, controlled trial
|
Gifford, Alex H.
|
|
|
24 |
1 |
p. 91-97
|
artikel
|
| 33 |
Suicidal behaviour and CFTR modulators: A case series and WHO database disproportionality analysis
|
Nidegger, Inès
|
|
|
24 |
1 |
p. 33-39
|
artikel
|
| 34 |
The impact of CFTR modulators on mental health: Moving the field forward
|
Georgiopoulos, AM
|
|
|
24 |
1 |
p. 5-7
|
artikel
|
| 35 |
Theranostics vs theratyping or theranostics plus theratyping?
|
Amaral, Margarida D.
|
|
|
24 |
1 |
p. 10-15
|
artikel
|
| 36 |
What does it mean to be “healthy” when taking elexacaftor/tezacaftor/ivacaftor (ETI)? A qualitative study
|
Everhart, Robin S.
|
|
|
24 |
1 |
p. 187-192
|
artikel
|
Tijdschrift beschrijving